Clinical Trials Logo

Second-line Treatment clinical trials

View clinical trials related to Second-line Treatment.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04522908 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma (HCC)

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

Start date: October 12, 2020
Phase: Phase 2
Study type: Interventional

Open-label, single arm, multicenter phase II trial assessing the tolerability of a reduced starting dose of 40 mg cabozantinib for 4 weeks and subsequent dose escalation to 60 mg cabozantinib until disease progression or intolerable toxicities.